417707-71-2

Upstream product

• 87326-32-7 allyl 2,3-di-O-benzyl-α-D-glucopyranoside 
• 98-59-9 p-toluenesulfonyl chloride 
• 2280-44-6 D-Glucose 
• 103833-57-4 allyl 4,6-O-benzylidene-2,3-di-O-benzyl-α-D-glucopyranoside 
• 93382-48-0 allyl 4,6-O-benzylidene-α-D-glucopyranoside 

Downstream Products

• 1234307-00-6 1-O-allyl-2,3-di-O-benzyl-4-O-(carbobenzoxy-β-alanyl)-6-O-tosyl-α-D-glucopyranoside 
• 1234307-16-4 3-O-[4-O-(4-iodobenzoyl-β-alanyl)-6-sulfo-α-D-quinovopyranosyl]-1,2-di-O-stearoyl-glycerol sodium salt 
• 1234307-01-7 C₃₆H₄₁NO₉S 
• 1234307-02-8 C₃₆H₄₃NO₁₁S 
• 1234307-03-9 C₅₄H₇₇NO₁₂S 
• 1234307-13-1 C₇₂H₁₁₁NO₁₃S 

Relevant academic research and scientific papers

Synthesis of unusual N-acylated aminosugar fragments of Mycobacterium marinum lipooligosaccharide IV

A convergent strategy was developed for the stereoselective synthesis of four unusual N-acylated monosaccharides (5-8), which are fragments of lipooligosaccharide IV (LOS-IV) from Mycobacterium marinum. A critical substrate-controlled asymmetric cyclization of an amino acid derived oxazolidine provided a key lactam intermediate 11, which was successfully converted to targets 5-7. The key step in the synthesis of 8 was a one-pot cascade oxidation-cyclization-oxidation reaction of a Boc-protected amino alcohol, prepared from 3-butynol, which led to the formation of lactam 15. The five-membered ring lactam intermediates in these synthetic routes were sensitive to elimination side reactions, but careful manipulation of the reaction sequence allowed for the stereoselective synthesis of the targets. This work represents the first synthesis of these unusual motifs, which have been shown to be essential to the bioactivity of LOS-IV.

COMPOUND RETAINED IN TUMOR

A novel compound which specifically resides in a tumor, a method for allowing it to reside in a tumor, and a method for detecting, diagnosing, and treating tumor with use thereof are provided. The present invention relates to a compound represented by chemical formula (I) wherein R is an anionic group binding to hydrogen, R1 is OH, OCOH, OCO(CH2)hCH3, or an acting group, h being an integer of 0 or more, R2 is H, OH, OCOH, OCO(CH2)iCH3, or an acting group, i being an integer of 0 or more, R3 is OH, SO3H, or an acting group, R4 is OH, SO3H, or an acting group, and R5 is OH, SO3H, or an acting group, at least one of R1, R2, R3, R4, and R5 containing an acting group, or pharmaceutically acceptable salts thereof.